Serum levels of Sex Hormone Binding Globulin (SHBG) are not predictive of prostate cancer diagnosis and aggressiveness: results from an italian biopsy cohort

Nunzio, Cosimo De; Lombardo, Riccardo; Albisinni, Simone; Gacci, Mauro; Tubaro, Andrea

doi:10.1590/s1677-5538.ibju.2013.06.04

Cited by 10 publications

(11 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In localized prostate cancer, the preoperative serum SHBG expression levels were associated with prostatic extension and Gleason score (29). SHBG was not considered a biomarker for high-grade disease (30). For future prostate cancer studies, normal reference values of SHBG should reflect sex and age.…”

Section: Discussionmentioning

confidence: 99%

Serum concentration of sex hormone‑binding globulin in healthy volunteers and patients with breast cancer stratified by sex and age

et al. 2020

View full text Add to dashboard Cite

The objective of the present study was to compare sex hormone-binding globulin (SHBG) levels according to sex (healthy male and female volunteers) and age to determine reference values. Serum SHBG expression levels in patients with breast cancer with different tumor burden states were also determined. A total of 109 samples were obtained from 34 patients in 3 different disease states (non-tumor, localized tumor and systemic metastasis) during follow-up. A sandwich ELISA was conducted to measure SHBG, cancer antigen (CA)15-3 and CA125 expression levels. Wilcoxon rank-sum tests were performed on non-normally distributed data and an unpaired t-test was used for normally distributed variables. SHBG expression levels were higher in females compared with males (P<0.0001). When SHBG expression levels were compared by sex, the difference was maintained in the age groups <30, 30-39 and ≥50 years, but not in the 40-49 years group. In males, SHBG expression levels increased until the age of 49 and then decreased (P=0.01). In females, SHBG expression levels exhibited a decreased trend until the age of 49 (P=0.66). In patients with breast cancer, the SHBG expression levels revealed a decreasing trend after the age of 50, which was different compared with the healthy females. There was a decreasing trend of SHBG expression levels from pre-menopause to post-menopause healthy volunteers (P=0.74). CA15-3 (r 2 =0.07; P=0.59) and CA 125 (r 2 =-0.18; P=0.17) levels did not exhibit any significant correlation with SHBG expression levels. There was a significant difference in the SHBG expression levels between male and female healthy volunteers. SHBG expression levels also revealed different patterns between healthy female volunteers and female patients with breast cancer ≥50 years of age. The present study demonstrated that SHBG does not have value as a biomarker, but different reference values according to age and sex may aid in predicting high-risk groups for hormone-dependent cancer and guide treatment direction for post-menopausal breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum concentration of sex hormone‑binding globulin in healthy volunteers and patients with breast cancer stratified by sex and age

et al. 2020

View full text Add to dashboard Cite

show abstract

“…High SHBG level has been associated with extraprostatic extension [25]. However, another study reported that SHBG level was not predictive of the diagnosis or aggressiveness of prostate cancer [26].…”

Section: Discussionmentioning

confidence: 99%

Luteinizing Hormone Levels Relate to the Unfavorable Pathology of Prostate Cancer

Choi

Hoon

Lee

et al. 2020

JCM

View full text Add to dashboard Cite

Purpose: This study analyzed the association between sex hormone concentrations and stage/condition in patients with prostate cancer. Materials and methods: The concentrations of sex hormones, including testosterone (total, free, and bioavailable), sex hormone-binding globulin (SHBG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH), were measured in 415 patients diagnosed with prostate cancer. Differences in serum hormone concentrations after receiving androgen deprivation therapy (ADT) and after withdrawal from ADT were evaluated. Pathologic characteristics were assessed in the 225 patients unexposed to ADT with a history of radical prostatectomy. Logistic regression analysis was performed to identify factors predictive of unfavorable pathology (Grade ≥3, ≥T3a, or N1). Results: Of the 415 prostate cancer patients, 130 (31.3%) were assessed before treatment, 171 (41.2%) after surgery, 35 (8.4%) after biochemical recurrence, and 59 (14.2%) during ADT, whereas 20 (4.8%) had castration-resistant prostate cancer. FSH was significantly lower after compared to before prostatectomy (3.229 ± 4.486 vs. 5.941 ± 7.044 mIU/mL, p < 0.001). LH, FSH, and testosterone decreased significantly 3 months after starting ADT, but increased 3 months after ADT withdrawal, whereas SHBG was unchanged. Multivariate analysis showed that high LH (odds ratio [OR]: 1.59, 95% confidence interval [CI]: 1.03–2.47, p = 0.0376) and prostate-specific antigen (PSA) (OR: 1.13, 95% CI: 1.03–1.24, p = 0.0133) concentrations were significantly associated with a high risk of unfavorable pathology. Conclusions: Sex hormones, including LH, FSH, and testosterone, were affected by ADT. The FSH level decreased after radical prostatectomy. High baseline LH concentration in patients unexposed to ADT was associated with an unfavorable pathology.

show abstract

“…Plasma retinol-binding protein 4 (plasma retinol-binding protein, PRBP) is synthesized in the liver and mediates retinol transport in blood [242]. PRBP is a sensitive marker of under-nutrition and the monitoring of its serum concentration allows the monitoring of nutritional status.…”

Section: Plasma Retinol-binding Protein (Ret4_human)mentioning

confidence: 99%

Construction of 2DE-Patterns of Plasma Proteins: Aspect of Potential Tumor Markers

Naryzhny¹,

Ронжина²,

Zorina³

et al. 2022

Preprint

View full text Add to dashboard Cite

Cancer is a complex systemic disease that changes the entire proteome. The analysis of this transformation makes it possible to determine tumor markers, that is, the most characteristic biomacromolecules produced by tumor cells. Here, the question of finding ideal tumor markers, which should be sensitive, specific, and reliable, is an acute issue. Unfortunately, none of the tumor markers, even those used in the clinic, has all these characteristics. Despite this, many tumor markers have demonstrated excellent clinical relevance for monitoring the effectiveness of different treatments for cancer patients. The use of markers also aids in the early detection of cancer recurrence and prognosis. Therefore, the situation in this area can be improved in two ways – by attempting to find an ideal single tumor marker or generating panels of different markers. In both cases, proteomics certainly plays a major role. Human plasma is one of the most popular samples as it is commonly collected in the clinic and provides noninvasive, rapid analysis for any type of disease including cancer. Many efforts have been applied in searching for “ideal” tumor markers digging very deep plasma proteome. There is a line of evidence that the most abundant, so-called “classical plasma proteins”, may be used to generate a tumor biomarker profile. To be comprehensive these profiles should have information not only about protein levels but proteoform distribution for each protein. Initially, the profile of these proteins in norm should be generated. Here, we present data about these profiles generated by two-dimensional electrophoresis with the following mass-spectrometry and immunodetection.

show abstract

Serum levels of Sex Hormone Binding Globulin (SHBG) are not predictive of prostate cancer diagnosis and aggressiveness: results from an italian biopsy cohort

Cited by 10 publications

References 29 publications

Serum concentration of sex hormone‑binding globulin in healthy volunteers and patients with breast cancer stratified by sex and age

Serum concentration of sex hormone‑binding globulin in healthy volunteers and patients with breast cancer stratified by sex and age

Luteinizing Hormone Levels Relate to the Unfavorable Pathology of Prostate Cancer

Construction of 2DE-Patterns of Plasma Proteins: Aspect of Potential Tumor Markers

Contact Info

Product

Resources

About